PARIS (Reuters) – Sanofi and GlaxoSmithKline said on Thursday they were launching Phase III trial, the late-stage before submitting approval, for their experimental COVID-19 vaccine.
Pending positive phase III outcome, the vaccine could be approved in the fourth quarter 2021 after having initially been targeted for the first half of this year before a setback.
Sanofi and GSK last December were forced to restart their trial when the vaccine showed a low immune response in older adults as a result of a weak antigen formulation.
(Reporting by Dominique Vidalon, Editing by Benoit Van Overstraeten)
